These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

302 related articles for article (PubMed ID: 29100885)

  • 1. A Phase II Clinical Trial of Low-Dose Inhaled Carbon Monoxide in Idiopathic Pulmonary Fibrosis.
    Rosas IO; Goldberg HJ; Collard HR; El-Chemaly S; Flaherty K; Hunninghake GM; Lasky JA; Lederer DJ; Machado R; Martinez FJ; Maurer R; Teller D; Noth I; Peters E; Raghu G; Garcia JGN; Choi AMK
    Chest; 2018 Jan; 153(1):94-104. PubMed ID: 29100885
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Low Dose Carbon Monoxide Exposure in Idiopathic Pulmonary Fibrosis Produces a CO Signature Comprised of Oxidative Phosphorylation Genes.
    Casanova N; Zhou T; Gonzalez-Garay ML; Rosas IO; Goldberg HJ; Ryter SW; Collard HR; El-Chemaly S; Flaherty KR; Hunninghake GM; Lasky JA; Lederer DJ; Machado RF; Martinez FJ; Noth I; Raghu G; Choi AMK; Garcia JGN
    Sci Rep; 2019 Oct; 9(1):14802. PubMed ID: 31615996
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effect of Recombinant Human Pentraxin 2 vs Placebo on Change in Forced Vital Capacity in Patients With Idiopathic Pulmonary Fibrosis: A Randomized Clinical Trial.
    Raghu G; van den Blink B; Hamblin MJ; Brown AW; Golden JA; Ho LA; Wijsenbeek MS; Vasakova M; Pesci A; Antin-Ozerkis DE; Meyer KC; Kreuter M; Santin-Janin H; Mulder GJ; Bartholmai B; Gupta R; Richeldi L
    JAMA; 2018 Jun; 319(22):2299-2307. PubMed ID: 29800034
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Allogeneic Human Mesenchymal Stem Cells in Patients With Idiopathic Pulmonary Fibrosis via Intravenous Delivery (AETHER): A Phase I Safety Clinical Trial.
    Glassberg MK; Minkiewicz J; Toonkel RL; Simonet ES; Rubio GA; DiFede D; Shafazand S; Khan A; Pujol MV; LaRussa VF; Lancaster LH; Rosen GD; Fishman J; Mageto YN; Mendizabal A; Hare JM
    Chest; 2017 May; 151(5):971-981. PubMed ID: 27890713
    [TBL] [Abstract][Full Text] [Related]  

  • 5. High Oxygen Delivery to Preserve Exercise Capacity in Patients with Idiopathic Pulmonary Fibrosis Treated with Nintedanib. Methodology of the HOPE-IPF Study.
    Ryerson CJ; Camp PG; Eves ND; Schaeffer M; Syed N; Dhillon S; Jensen D; Maltais F; O'Donnell DE; Raghavan N; Roman M; Stickland MK; Assayag D; Bourbeau J; Dion G; Fell CD; Hambly N; Johannson KA; Kalluri M; Khalil N; Kolb M; Manganas H; Morán-Mendoza O; Provencher S; Ramesh W; Rolf JD; Wilcox PG; Guenette JA
    Ann Am Thorac Soc; 2016 Sep; 13(9):1640-7. PubMed ID: 27348402
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A novel formulation of inhaled sodium cromoglicate (PA101) in idiopathic pulmonary fibrosis and chronic cough: a randomised, double-blind, proof-of-concept, phase 2 trial.
    Birring SS; Wijsenbeek MS; Agrawal S; van den Berg JWK; Stone H; Maher TM; Tutuncu A; Morice AH
    Lancet Respir Med; 2017 Oct; 5(10):806-815. PubMed ID: 28923239
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effects of Qizhukangxian granules on idiopathic pulmonary fibrosis: a randomized, double blind, placebo-controlled and multicenter clinical pilot trial.
    Guo S; Song Y; Feng J; Liu S; Li Y; Liu M; Wei L; Zhang X; Xie H; Sun Z
    J Tradit Chin Med; 2020 Aug; 40(4):674-682. PubMed ID: 32744035
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Randomized, Double-Blind, Placebo-Controlled, Phase 2 Trial of BMS-986020, a Lysophosphatidic Acid Receptor Antagonist for the Treatment of Idiopathic Pulmonary Fibrosis.
    Palmer SM; Snyder L; Todd JL; Soule B; Christian R; Anstrom K; Luo Y; Gagnon R; Rosen G
    Chest; 2018 Nov; 154(5):1061-1069. PubMed ID: 30201408
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy and safety of Kangxian Huanji Granule as adjunctive treatment in acute exacerbation of idiopathic pulmonary fibrosis: An exploratory randomized controlled trial.
    Li JS; Zhang HL; Guo W; Wang L; Zhang D; Zhao LM; Zhou M
    J Integr Med; 2023 Nov; 21(6):543-549. PubMed ID: 37993378
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The Efficacy and Mechanism Evaluation of Treating Idiopathic Pulmonary fibrosis with the Addition of Co-trimoxazole (EME-TIPAC): study protocol for a randomised controlled trial.
    Hammond M; Clark AB; Cahn AP; Chilvers ER; Fraser WD; Livermore DM; Maher TM; Parfrey H; Swart AM; Stirling S; Thickett D; Whyte M; Wilson A
    Trials; 2018 Feb; 19(1):89. PubMed ID: 29402332
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Safety and tolerability of acetylcysteine and pirfenidone combination therapy in idiopathic pulmonary fibrosis: a randomised, double-blind, placebo-controlled, phase 2 trial.
    Behr J; Bendstrup E; Crestani B; Günther A; Olschewski H; Sköld CM; Wells A; Wuyts W; Koschel D; Kreuter M; Wallaert B; Lin CY; Beck J; Albera C
    Lancet Respir Med; 2016 Jun; 4(6):445-53. PubMed ID: 27161257
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Treatment of idiopathic pulmonary fibrosis with etanercept: an exploratory, placebo-controlled trial.
    Raghu G; Brown KK; Costabel U; Cottin V; du Bois RM; Lasky JA; Thomeer M; Utz JP; Khandker RK; McDermott L; Fatenejad S
    Am J Respir Crit Care Med; 2008 Nov; 178(9):948-55. PubMed ID: 18669816
    [TBL] [Abstract][Full Text] [Related]  

  • 13. BUILD-3: a randomized, controlled trial of bosentan in idiopathic pulmonary fibrosis.
    King TE; Brown KK; Raghu G; du Bois RM; Lynch DA; Martinez F; Valeyre D; Leconte I; Morganti A; Roux S; Behr J
    Am J Respir Crit Care Med; 2011 Jul; 184(1):92-9. PubMed ID: 21474646
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Zinpentraxin Alfa for Idiopathic Pulmonary Fibrosis: The Randomized Phase III STARSCAPE Trial.
    Richeldi L; Schiffman C; Behr J; Inoue Y; Corte TJ; Cottin V; Jenkins RG; Nathan SD; Raghu G; Walsh SLF; Jayia PK; Kamath N; Martinez FJ
    Am J Respir Crit Care Med; 2024 May; 209(9):1132-1140. PubMed ID: 38354066
    [No Abstract]   [Full Text] [Related]  

  • 15. Low-dose oral theophylline combined with inhaled corticosteroids for people with chronic obstructive pulmonary disease and high risk of exacerbations: a RCT.
    Devereux G; Cotton S; Fielding S; McMeekin N; Barnes PJ; Briggs A; Burns G; Chaudhuri R; Chrystyn H; Davies L; Soyza A; Gompertz S; Haughney J; Innes K; Kaniewska J; Lee A; Morice A; Norrie J; Sullivan A; Wilson A; Price D
    Health Technol Assess; 2019 Jul; 23(37):1-146. PubMed ID: 31343402
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Design of the INPULSIS™ trials: two phase 3 trials of nintedanib in patients with idiopathic pulmonary fibrosis.
    Richeldi L; Cottin V; Flaherty KR; Kolb M; Inoue Y; Raghu G; Taniguchi H; Hansell DM; Nicholson AG; Le Maulf F; Stowasser S; Collard HR
    Respir Med; 2014 Jul; 108(7):1023-30. PubMed ID: 24834811
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pirfenidone plus inhaled N-acetylcysteine for idiopathic pulmonary fibrosis: a randomised trial.
    Sakamoto S; Kataoka K; Kondoh Y; Kato M; Okamoto M; Mukae H; Bando M; Suda T; Yatera K; Tanino Y; Kishaba T; Hattori N; Taguchi Y; Saito T; Nishioka Y; Kuwano K; Kishi K; Inase N; Sasaki S; Takizawa H; Johkoh T; Sakai F; Homma S;
    Eur Respir J; 2021 Jan; 57(1):. PubMed ID: 32703779
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pirfenidone in patients with idiopathic pulmonary fibrosis and more advanced lung function impairment.
    Nathan SD; Costabel U; Albera C; Behr J; Wuyts WA; Kirchgaessler KU; Stauffer JL; Morgenthien E; Chou W; Limb SL; Noble PW
    Respir Med; 2019 Jul; 153():44-51. PubMed ID: 31153107
    [TBL] [Abstract][Full Text] [Related]  

  • 19. BUILD-1: a randomized placebo-controlled trial of bosentan in idiopathic pulmonary fibrosis.
    King TE; Behr J; Brown KK; du Bois RM; Lancaster L; de Andrade JA; Stähler G; Leconte I; Roux S; Raghu G
    Am J Respir Crit Care Med; 2008 Jan; 177(1):75-81. PubMed ID: 17901413
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Impact of angiopoietin-1 and -2 on clinical course of idiopathic pulmonary fibrosis.
    Uehara M; Enomoto N; Mikamo M; Oyama Y; Kono M; Fujisawa T; Inui N; Nakamura Y; Suda T
    Respir Med; 2016 May; 114():18-26. PubMed ID: 27109807
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.